[CAS NO. 437-74-1] Xanthinol Nicotinate
PRODUCTS SPECIFICATIONS [437-74-1]
DESCRIPTION [437-74-1]
Overview
| MDL | MFCD00058342 |
|---|---|
| Molecular Weight | 434.45 |
| Molecular Formula | C19H26N6O6 |
| SMILES | O=C(C1=CC=CN=C1)O.O=C(N2C)N(C)C3=C(N(CC(O)CN(CCO)C)C=N3)C2=O |
Summary
In Vitro
Xanthinol Nicotinate (Xanthinol Niacinate; 2.76-276 µM; for 24 hours) inhibits HUASMC proliferation in a dose-dependent manner
[2]
.
Xanthinol Nicotinate (2.76-276 µM; for 24 hours) dose-dependently decreases the PDGFR mRNA and PDGFR-β levels on the cell membranes of HUASMCs
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [2]
| Cell Line: | human umbilical artery smooth muscle cell (HUASMC) |
| Concentration: | 2.76, 27.6 or 276 µM |
| Incubation Time: | for 24 hours |
| Result: | Inhibited HUASMC proliferation in a dose-dependent manner. |
Western Blot Analysis [2]
| Cell Line: | HUASMC |
| Concentration: | 2.76, 27.6 or 276 µM |
| Incubation Time: | for 24 hours |
| Result: | Dose-dependently decreased the PDGFR mRNA and PDGFR-β levels on the cell membranes of HUASMCs. |
In Vivo
Xanthinol Nicotinate (Xanthinol Niacinate; 75 mg/kg; IP) rapidly and transiently modifies tumor pO
2
and the maximal pO
2
values are obtained 10 to 30 minutes after Xanthinol Nicotinate administration
[1]
.
Xanthinol Nicotinate is able to radiosensitize the tumors when applying 10 Gy of X-Rays during the reoxygenation of the tumors (enhancement in radiation response of 1.4)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 5 week-old male NMRI mice [1] |
| Dosage: | 75 mg/kg |
| Administration: | IP |
| Result: | Rapidly and transiently modified tumor pO 2 and Maximal pO 2 values were obtained 10 to 30 minutes after XN administration. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 250 mg/mL ( 575.44 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3018 mL | 11.5088 mL | 23.0176 mL |
| 5 mM | 0.4604 mL | 2.3018 mL | 4.6035 mL |
| 10 mM | 0.2302 mL | 1.1509 mL | 2.3018 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (115.09 mM); Clear solution; Need ultrasonic
References
- [1] Segers J, et al. Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors. Int J Cancer. 2010 Jan 15;126(2):583-8.
- [2] Bai X, et al. Inhibited proliferation of human umbilical artery smooth muscle cells by xanthinol nicotinate. Med Biol Eng Comput. 2016 Jun;54(6):891-8.
Synonyms